Opendata, web and dolomites

D2P SIGNED

Diabeloop to Patients: An Artificial Pancreas solution to improve the balance, safety and autonomy of 20 million people

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 D2P project word cloud

Explore the words cloud of the D2P project. It provides you a very rough idea of what is the project "D2P" about.

delivered    daily    mimic    anyone    autoimmune    reduce    complications    specificities    function    healthy    physiological    destruction    alleviate    t1d    sweden    hypoglycaemia    basis    cells    causes    hosting    adoption    hyperglycaemia    generation    people    heart    france    core    worldwide    day    performances    healthcare    producing    personalised    regulation    pancreas    upgrade    periods    coma    million    glucose    industrialisation    closed    foreign    dblg1    first    models    automatically    burden    blindness    algorithms    identification    sensor    situations    patient    components    professional    goals    adjustments    made    exchange    regulating    solution    20    seizures    diabetes    breakthrough    intelligence    amputations    market    calculate    fainting    diseases    treatment    severe    customisation    dose    renal    storage    monitoring    complementary    stressful    telemedicine    continuous    begin    countries    handset    suggest    integrates    device    optimisation    half    countless    telemonitoring    patients    appropriate    netherlands    secured    artificial    clinicians    loop    pump    beta    data    validate    age    model    death    innovation    insulin    connected    diabeloop   

Project "D2P" data sheet

The following table provides information about the project.

Coordinator
DIABELOOP 

Organization address
address: 155-157 COURS BERRIAT
city: GRENOBLE
postcode: 38028
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 2˙793˙190 €
 EC max contribution 1˙955˙233 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DIABELOOP FR (GRENOBLE) coordinator 1˙955˙233.00

Map

 Project objective

20 million people worldwide are affected by type 1 diabetes (T1D), an autoimmune condition leading to the destruction of beta cells of the pancreas producing insulin. T1D causes severe complications: short terms - seizures and fainting that could result in coma or even death; long terms - blindness, amputations, renal failure, heart diseases. T1D can occur to anyone and half of the cases begin before age 20. T1D patients have to manage their diabetes on a daily basis, facing countless stressful situations.

Diabeloop’s “artificial pancreas” solution aims to mimic the glucose regulating function of a healthy pancreas. The core of our “artificial pancreas” solution is an artificial intelligence: algorithms based on physiological models continuously calculate the most appropriate and personalised dose of insulin. Insulin is then automatically delivered to the patient. Diabeloop goals are to reduce hypoglycaemia and hyperglycaemia periods, alleviate the day-to-day burden and avoid long-term complications.

Diabeloop’s first generation solution (DBLG1) is integrated in a closed-loop system made of three components: a continuous glucose monitoring sensor, a connected insulin pump, and a handset hosting algorithms and controlling the pump. Diabeloop’s solution integrates a telemedicine program through highly secured data exchange, storage and healthcare professional identification. Clinicians may access the patients’ data and suggest treatment adjustments as necessary, for an improved system customisation and long-term regulation. During the phase 2 project, we scale up and target a European adoption of our breakthrough innovation. We focus on France, the Netherlands and Sweden, 3 countries with complementary specificities to validate our model: adaptation of the device to foreign market, optimisation of performances, telemonitoring upgrade and industrialisation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "D2P" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "D2P" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More